Ionis Pharma EVP Baroldi sells $1.95m in shares

Joseph Baroldi, Executive Vice President and Chief Business Officer at IONIS PHARMACEUTICALS INC (NASDAQ:IONS), sold 32,800 shares of common stock on September 3, 2025, for approximately $1.95 million. The sales were executed at weighted average prices ranging from $59.0864 to $62.0101, near the stock’s 52-week high of $62.08. The transaction comes as IONS shares have surged 39.2% in the past week alone.

The sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 2, 2025.

On the same day, Baroldi also exercised options to acquire 32,800 shares of IONIS PHARMACEUTICALS INC common stock at a price of $31.8 per share, for a total value of $1043040.

Following these transactions, Baroldi directly owns 16,926 shares of IONIS PHARMACEUTICALS INC. common stock. Additionally, Baroldi indirectly owns 3,071 shares through a spouse. With a market capitalization of $9.47 billion, IONS trades at a premium price-to-book ratio of 14.97x. Discover more insights and 12 additional ProTips with InvestingPro.

In other recent news, Ionis Pharmaceuticals has been at the center of attention with significant developments. The company reported positive topline results from its Phase 3 CORE and CORE2 trials for severe hypertriglyceridemia, which led to a 32% surge in its stock. These trials demonstrated statistically significant benefits, notably in triglyceride lowering and reducing the risk of acute pancreatitis. Following these results, RBC Capital raised its price target for Ionis Pharmaceuticals to $80, citing the promising potential of their acute pancreatitis treatment. Similarly, H.C. Wainwright increased its price target to $95, acknowledging strong triglyceride reductions in pivotal studies. BMO Capital upgraded Ionis Pharmaceuticals to Outperform, highlighting the blockbuster potential of Olezarsen, which exceeded expectations. Additionally, Oppenheimer raised its price target to $81 after the positive Phase 3 trial results for Tryngolza in treating severe hypertriglyceridemia. These developments reflect a growing confidence among analysts in Ionis Pharmaceuticals’ recent advancements.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.